Back to Search Start Over

Sulfonylhydrazones: Design, synthesis and investigation of ectonucleotidase (ALP & e5'NT) inhibition activities.

Authors :
Younus HA
Hameed A
Mahmood A
Khan MS
Saeed M
Batool F
Asari A
Mohamad H
Pelletier J
Sévigny J
Iqbal J
Al-Rashida M
Source :
Bioorganic chemistry [Bioorg Chem] 2020 Jul; Vol. 100, pp. 103827. Date of Electronic Publication: 2020 Apr 08.
Publication Year :
2020

Abstract

Medicinal importance of the sulfonylhydrazones is well-evident owing to their binding ability with zinc containing metalloenzymes. In the present study, we have synthesized different series of sulfonylhydrazones by using facile synthetic methods in good to excellent yield. All the successfully prepared sulfonylhydrazones were screened for ectonucleotidase (ALP & e5'NT) inhibitory activity. Among the chromen-2-one scaffold based sulfonylhydrazones, the compounds 7 was found to be most potent inhibitor for h-TNAP (human tissue non-specific alkaline phosphatase) and h-IAP (human intestinal alkaline phosphatase) with IC <subscript>50</subscript> values of 1.02 ± 0.13 and 0.32 ± 0.0 3 µM respectively, compared with levamisole (IC <subscript>50</subscript>  = 25.2 ± 1.90 µM for h-TNAP) and l-phenylalanine (IC <subscript>50</subscript>  = 100 ± 3.00 µM for h-IAP) as standards. Further, the chromen-2-one based molecule 5a showed excellent activity against h-ecto 5'-NT (human ecto-5'-nucleotidase) with IC <subscript>50</subscript> value of 0.29 ± 0.004 µM compared to standard, sulfamic acid (IC <subscript>50</subscript>  = 42.1 ± 7.8 µM). However, among the series of phenyl ring based sulfonylhydrazones, compound 9d was found to be most potent against h-TNAP and h-IAP with IC <subscript>50</subscript> values of 0.85 ± 0.08 and 0.52 ± 0.03 µM, respectively. Moreover, in silico studies were also carried to demonstrate their putative binding with the target enzymes. The potent compounds 5a, 7, and 9d against different ectonucleotidases (h-ecto 5'-NT, h-TNAP, h-IAP) could potentially serve as lead for the development of new therapeutic agents.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1090-2120
Volume :
100
Database :
MEDLINE
Journal :
Bioorganic chemistry
Publication Type :
Academic Journal
Accession number :
32402802
Full Text :
https://doi.org/10.1016/j.bioorg.2020.103827